Containment, In-Vivo, Pharma Companies and Regulation

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Containment

In-Vivo

Pharma Companies

Regulation

Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective

Pharmaceutical Technology

MAY 24, 2023

Every major pharma company is now involved in CGT development which has resulted in the approval of 28 therapies by the FDA thereby making CGT no longer a niche category of therapies. What are the general differences in the supply chain of CGT vs. traditional clinical trials? Differences in CGT vs traditional trials supply chain.

Clinical Trials

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain

In the News: October Regulatory and Development Updates

Camargo

NOVEMBER 11, 2020

In October, Antares Pharma licensed Ferring Pharmaceuticals’ Nocdurna® (desmopressin acetate) sublingual tablet , which was approved in 2018 for the same indication as Noctiva and has a boxed warning highlighting the same risks. Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. In October, the U.S.

Development

Development Bioequivalency Generic Drugs Production

Clinical Research Informer

Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective

In the News: October Regulatory and Development Updates

Stay Connected